Business Wire21d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
Please see full Prescribing Information for AREXVY. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Medical News Today27d
Boostrix side effects: What you should know
For more information, you can refer to Boostrix’s prescribing information. Mild side effects that have been reported with Boostrix include: fever headache fatigue injection site reactions ...
Benzinga.com20d
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK's Arexvy shows strong immune response in adults aged 18-49 at risk for RSV-related respiratory disease. Over 21 million U.S. adults aged 18-49 may be at risk for RSV due to underlying conditions.
Business Insider21d
GSK reports preliminary data for AREXVY
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...
Hosted on MSN11mon
What It’s Like to Have RSV as an Older Adult
Talk to your doctor or visit www.AREXVY.com to learn more. Please see full Prescribing Information. You are encouraged to report vaccine adverse events to the US Department of Health and Human ...
Stockhouse1mon
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY(Respiratory ...
McKnight's Long-Term Care News1mon
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...
pharmaphorum5mon
Moderna gets FDA okay for RSV vaccine mResvia
mResvia’s prescribing information indicates that the vaccine ... mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding ...
University of Manchester1d
Independent Prescribing (Short Course)
To avoid delays, please start by reading our nomination pack, which contains guidance on completing the IP application form, FAQs and information about the roles and responsibilities of the Designated ...